publication venue for
- TRSC-04 DE NOVO GTP SYNTHESIS IS A METABOLIC VULNERABILITY FOR THE INTERCEPTION OF BRAIN METASTASES. 6:i40-i40. 2024
- BSBM-09 IN VIVO CRISPR ACTIVATION SCREEN IDENTIFIES ß-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) AS A DRIVER OF NON-SMALL CELL LUNG CANCER BRAIN METASTASIS. 5:iii2-iii2. 2023
- SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS. 5:iii33-iii33. 2023
- SYST-28 FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND A NOVEL TARGETABLE PTP4A2-ROBO1 SIGNALING AXIS AT GLIOBLASTOMA RECURRENCE. 5:iii33-iii33. 2023
- SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA. 5:iii34-iii34. 2023
- AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA. 5:i6-i6. 2023
- GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS. 5:i1-i2. 2023
- INTERCEPTING BRAIN METASTASES THROUGH METABOLIC VULNERABILITIES. 5:i2-i2. 2023
- ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER. 5:i3-i3. 2023
- UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA. 5:i10-i10. 2023
- Dissecting the tumor microenvironment of epigenetically driven gliomas: Opportunities for single-cell and spatial multiomics. 5:vdad101. 2023
- BSCI-13 DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. 4:i3-i3. 2022
- BSCI-22 DETERMINING THE EFFECT OF NOVEL SMALL MOLECULE DRUGS AGAINST THE MIGRATION OF BRAIN METASTASIS INITIATING CELLS (BMICS). 4:i5-i5. 2022
- SYST-15 TARGETING AXONAL GUIDANCE WITH ANTI-ROBO1 CAR T CELLS: A NEW THERAPEUTIC STRATEGY FOR MALIGNANT BRAIN CANCER. 4:i24-i24. 2022
- Reoperation in adult patients with recurrent glioblastoma: A matched cohort analysis. 4:vdac115. 2022
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. 3:iii5-iii5. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. 3:ii5-ii5. 2021
- Identification of five important genes to predict glioblastoma subtypes. 3:vdab144. 2021
- 25. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF NCCTG N107C/CEC.3 AND N0574 (ALLIANCE) RANDOMIZED CLINICAL TRIALS. 2:ii4-ii4. 2020
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. 2:ii9-ii9. 2020
- 60. IDEAL TREATMENT REGIMEN FOR PATIENTS WITH ≥1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. 2:ii12-ii13. 2020
- Cervicomedullary hemangioblastoma treated with bevacizumab. 2:vdaa076. 2020
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. 1:i5-i5. 2019
- RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933. 1:i22-i22. 2019